Biotechnology finds a new form of funding with Crowdfunding and Spain is one of the pioneers

, ,
Integral service around a transaction
BY : Diego GutiérrezJuly Thu, 2015
Faced with the difficulty biotech companies have in finding both private and public funding, they are turning to crowdfunding. This year, Spain has created the first European platform and the second worldwide for biotech crowdfunding. Although the operations closed in Spain are still of a small amount, operations closed in biotechnology in other parts of the world, such as that of Cell Therapheutics for almost €1M, show that it is a form of financing that will eventually have a significant impact on the sector. In addition, the public sector has also launched a crowdfunding platform in the biotech sector.


crowdfunding biotech sector
CapitalCell first biotech crowdequity platform in Europe

CapitalCell, is the investment crowdfunding platform dedicated to Health and Biotechnology was founded in 2014 in Barcelona by experts from other crowdfunding platforms with the aim of contributing to innovation in the Spanish biotechnology sector.

Capital Cell is the first crowdequity platform in Europe and the second worldwide that has already closed three projects since it started its activity in companies. Iproteos, Zeclinics and Immune Tolerance, the three projects have won a total amount of €100,000.

At present, the company SM Genomicshas launched a €150,000 crowdfunding round on Capitall Cell to finance the introduction in the Spanish amateur sports market of its Injury Genetic Report (IGL), a test to assess an athlete's predisposition to suffer non-contact muscle, ligament and tendon injuries, and to estimate the severity and recovery time.

"In addition to the crowdequity campaign, the company will also run a capital increase 300,000, reserved for business angels and venture capital companies" says Diego Gutierrez of Abra-Invest.

Precipita, the Spanish start-up for public biotech crowdfunding
The Spanish Foundation for Science and Technology (FECYT) launched in 2014 Precipitates, a project defined as a "meeting point for researchers and people interested in science" which has already funded 14 projects.

The projects that appear on the platform must have previously passed a public call for proposals. Each project has 90 days to reach the minimum target that each research has set, the maximum amount that can be obtained is €25,000.
An example of a company that has raised €20,000 thanks to the platform is Brainful Legends, a cognitive stimulation video game, aimed at learning competences and skills, both specific and general, for people with disabilities.
If you are looking for financing, please contact us. ABRA-INVEST, has a team of experts in alternative financing for biotechnology. Phone +34 946424142


Other posts that may interest you

Gesgenerics and OWL: M&A biotech sector in June 2015

Biotechnology grows and finds ways to finance it

The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?